Akari Therapeutics to Present at the JMP 2016 Life Sciences Conference
June 15, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, June 15, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference
May 26, 2016 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome
May 23, 2016 07:10 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
May 19, 2016 07:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin...
Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome
May 12, 2016 16:05 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
April 14, 2016 07:30 ET
|
Akari Therapeutics Plc
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a...
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
March 31, 2016 16:03 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...
Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
March 01, 2016 07:15 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 01, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that Gur Roshwalb, M.D.,...
Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day
February 17, 2016 07:15 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that members of its...
Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
January 29, 2016 07:05 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the approval by the UK...